Upon analyzing the influence of baseline criteria on their incidence, hematological malignancies were predicted to increase the odds of hematological complications upon treatment with anti-PD1 and anti-PD-L1 [OR = 17.18; 95% CI 4.06–72.71]. This evidence concerns the gene PDCD1 and hematologic disorder.